Key clinical point: Budesonide/formoterol has a better sepsis safety profile than fluticasone/salmeterol in long-term treatment for chronic obstructive pulmonary disease (COPD).
Major finding: Fluticasone/salmeterol had higher rates vs. budesonide/formoterol of sepsis (adjusted hazard ratio [aHR] = 1.15 and septic shock (aHR=1.149).
Study details: Retrospective analysis of patients with COPD who received fluticasone/salmeterol (n=10,267) or budesonide/formoterol (n=6,844).
Disclosures: The study was funded by the Taiwan National Science Foundation, Cardinal Tien Hospital and National Health Research Institutes Study. The authors report no disclosures.
Wang C-Y et al. Aging (Albany NY). 2019 Sep 10;11(17):6863-6871.